A Phase 1/2 interventional study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells in Macular Degenerative Disease, sponsored by Astellas Institute for Regenerative Medicine. Enrolling by invitation at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.
Sponsored by Astellas Institute for Regenerative Medicine (part of Astellas Pharma Inc) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to is to evaluate the occurrence of late onset (i.e., greater than 5 years after treatment) adverse events of special interest (AESI) in participants who have received sub-retinal transplant of human embryonic stem cell derived - retinal pigment epithelial (hESC-RPE) cells in an AIRM-sponsored clinical trial. The events of special interest are adverse events (AEs) that are presumed to have a potential causal relationship to the hESC-RPE cells.
Participants will be contacted by the Patient Outreach Center (POC) on an annual basis to complete a questionnaire about the occurrence of AESI, as defined in the Outcome Measure section.
The questionnaire will be completed directly by the participant (via a secure web based platform) or will be administered via telephone by a POC staff member. In the event of the occurrence of a AESI, study participant will be encouraged to contact the POC as soon as possible, rather than wait for the annual questionnaire completion. Follow up data is inclusive of the 1 year in the core trial, 4 years in the long term follow up trial and 10 years in this long term safety follow up. Participation for United Kingdom participants will be life-long.
Astellas Institute for Regenerative Medicine is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
First submitted after Astellas Institute for Regenerative Medicine became part of Astellas Pharma Inc.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants previously enrolled into an Astellas Institute for Regenerative Medicine (AIRM) sponsored clinical trial and treated with Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial (hESC-RPE) cells
Biological: Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells
Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial
Also known as: ASP7316
Number of adverse events (AEs) that are ophthalmologic, neurologic, infectious or hematologic
Adverse events (AEs) will be coded using Medical Dictionary for Regulatory Activities (MedDRA). Participant self-reported via an annual questionnaire of adverse events that are ophthalmologic, neurologic, infectious or hematologic.
Time frame: Up to 15 Years
Number of new diagnoses of an immune-mediated disorder
Any new diagnosis of an immune-mediated disorder will be participant self-reported via an annual questionnaire.
Time frame: Up to 15 Years
Incidents of new cancer, irrespective of prior history
Any new cancer, irrespective of prior history, will be participant self-reported via an annual questionnaire.
Time frame: Up to 15 Years
Incidents of hESC-RPE cell proliferation
Occurrence of human embryonic stem cell derived - retinal pigment epithelial (hESC-RPE) cell proliferation will be participant self-reported via an annual questionnaire.
Time frame: Up to 15 Years
Incidents of ectopic tissue (RPE or non-RPE) formation
Occurrence of ectopic tissue (retinal pigment epithelial \[RPE\] or non-RPE) will be participant self-reported via an annual questionnaire
Time frame: Up to 15 Years
Number of participant reported pregnancies or pregnancy of participant's partner
Occurrence of pregnancy will be participant self-reported via an annual questionnaire
Time frame: Up to 15 Years
Number of reported pregnancy outcome(s)
Occurrence of pregnancy outcomes will be participant self-reported via an annual questionnaire
Time frame: Up to 15 Years
All cause death
All causes of death will be collected via an annual questionnaire (through participant-designated secondary contacts)
Time frame: Up to 15 Years
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
No publications or documents are linked to this record.
Started Jan 2018 (actual). Primary completion is estimated for Mar 2029, 134 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Astellas Institute for Regenerative Medicine →